DePuy Synthes announced new clinical evidence suggesting positive performance of the ATTUNE® Knee System.
Implant survivorship data from the National Joint Registry (NJR) for England, Wales, Northern Ireland and the Isle of Man has demonstrated results for the performance of ATTUNE that compare favorably to the class of cemented total knees.
Further, analysis of a large U.S. hospital admin database indicates that ATTUNE patients had 39% lower adjusted odds of discharge to a skilled nursing facility vs. those receiving a competitor’s total knee.
Per the 2016 NJR, the ATTUNE Knee estimated cumulative percent revision was 1.39% at 3 years (98.61% survivorship) for 4,463 knees, comparing favorably to the class of Cemented Total Knee Arthroplasty that has an estimated cumulative percent revision of 1.50%.
The ATTUNE system is consistently cited among growth drivers for DePuy’s orthopaedic revenue, as shown in this profile of activity for the company.
DePuy Synthes announced new clinical evidence suggesting positive performance of the ATTUNE® Knee System.
Implant survivorship data from the National Joint Registry (NJR) for England, Wales, Northern Ireland and the Isle of Man has demonstrated results for the performance of ATTUNE that compare favorably to the class of cemented total...
DePuy Synthes announced new clinical evidence suggesting positive performance of the ATTUNE® Knee System.
Implant survivorship data from the National Joint Registry (NJR) for England, Wales, Northern Ireland and the Isle of Man has demonstrated results for the performance of ATTUNE that compare favorably to the class of cemented total knees.
Further, analysis of a large U.S. hospital admin database indicates that ATTUNE patients had 39% lower adjusted odds of discharge to a skilled nursing facility vs. those receiving a competitor’s total knee.
Per the 2016 NJR, the ATTUNE Knee estimated cumulative percent revision was 1.39% at 3 years (98.61% survivorship) for 4,463 knees, comparing favorably to the class of Cemented Total Knee Arthroplasty that has an estimated cumulative percent revision of 1.50%.
The ATTUNE system is consistently cited among growth drivers for DePuy’s orthopaedic revenue, as shown in this profile of activity for the company.
Copy to clipboard 
